Microvascular Therapeutics to Present Phase II CardiSon™ Data at 40th International Bubble Conference in Chicago
Next-generation ultrasound enhancing agent demonstrated improved left ventricular opacification and significantly reduced acoustic shadowing
Chicago, IL, October 02, 2026 --(PR.com)-- Microvascular Therapeutics, Inc. (MVT), a clinical-stage biotechnology and medical-device company developing diagnostic and therapeutic ultrasound technologies, today announced that Evan Unger, M.D., FACR, CEO and Executive Chairman, will present preclinical and clinical data on MVT-100 (CardiSon™) at the 40th International Bubble Conference, being held October 1–2, 2026, in Chicago.
Dr. Unger’s presentation, “Next Generation Contrast Agents,” will take place Friday, October 2, during Session VII: Advanced Applications 2, is scheduled from 9:45–11:00 a.m. The presentation will highlight results from MVT’s prospective Phase II clinical study comparing CardiSon with Definity®, together with preclinical characterization, stability, imaging and renal-retention data.
In the randomized clinical study, healthy volunteers received dilute bolus doses of either MVT-100 or Definity. Three independent, blinded expert echocardiographers evaluated left ventricular opacification, endocardial border delineation and acoustic shadowing. CardiSon demonstrated a statistically significant shift toward higher left ventricular opacification scores compared with Definity (χ² = 14.73; p = 0.002). Across the clinical analyses presented, MVT-100 demonstrated significantly greater contrast enhancement and significantly less acoustic shadowing. No serious adverse events were reported in either study arm. There were no clinically meaningful adverse laboratory trends, and vital signs, electrocardiographic parameters, oxygen saturation, and respiratory rate remained stable throughout dosing and observation.
Preclinical formulation studies demonstrated substantially less lipid degradation for MVT-100 than Definity under accelerated storage conditions. MVT believes the improved formulation stability may contribute to CardiSon’s prolonged storage profile. Currently marketed Definity requires refrigerated storage before activation, whereas CardiSon will be stored at room temperature. In animal studies, MVT-100 also demonstrated substantially lower renal retention than Definity.
“CardiSon was designed to improve both the clinical imaging performance and practical product characteristics of currently available ultrasound enhancing agents,” said Dr. Unger. “The Phase II results are particularly encouraging because the improvements in left ventricular opacification and reduction in acoustic shadowing were observed by independent blinded readers. The formulation stability and lower renal retention seen in our preclinical studies provide additional evidence of meaningful product differentiation and support continued pivotal development of CardiSon.”
MVT-100 is being developed as an ultrasound enhancing agent for echocardiography. The company’s broader technology platform also includes microbubble and nanobubble-based products for diagnostic and therapeutic ultrasound applications, including CardiSon™, Solv™ and NanoBlate™.
The 40th International Bubble Conference brings together global leaders in cardiology, radiology, vascular medicine, pediatrics and ultrasound research to discuss advances in contrast-enhanced ultrasound and emerging diagnostic and therapeutic applications.
About Microvascular Therapeutics
Microvascular Therapeutics, Inc. is a clinical-stage biotechnology and medical-device company developing next-generation microbubble and nanobubble technologies for diagnostic and therapeutic ultrasound. The company’s lead program, CardiSon™ (MVT-100), is being developed as a next-generation ultrasound enhancing agent for echocardiography. MVT is also developing therapeutic ultrasound platforms for cardiovascular disease and oncology.
For more information, visit www.mvtpharma.com.
Media/Investor Contact
Evan Unger, M.D., FACR
CEO & Executive Chairman
Microvascular Therapeutics, Inc.
e.unger@mvtpharma.com
(520) 730-3264
Forward-Looking Statements
This press release contains forward-looking statements regarding the development, regulatory progress and potential clinical and commercial applications of MVT-100 and other MVT product candidates. These statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied. MVT-100 is an investigational product and has not been approved by the U.S. Food and Drug Administration.
Trademark Notice
DEFINITY® is a registered trademark of Lantheus Medical Imaging, Inc. Microvascular Therapeutics, Inc. is not affiliated with or endorsed by Lantheus Medical Imaging, Inc.
Dr. Unger’s presentation, “Next Generation Contrast Agents,” will take place Friday, October 2, during Session VII: Advanced Applications 2, is scheduled from 9:45–11:00 a.m. The presentation will highlight results from MVT’s prospective Phase II clinical study comparing CardiSon with Definity®, together with preclinical characterization, stability, imaging and renal-retention data.
In the randomized clinical study, healthy volunteers received dilute bolus doses of either MVT-100 or Definity. Three independent, blinded expert echocardiographers evaluated left ventricular opacification, endocardial border delineation and acoustic shadowing. CardiSon demonstrated a statistically significant shift toward higher left ventricular opacification scores compared with Definity (χ² = 14.73; p = 0.002). Across the clinical analyses presented, MVT-100 demonstrated significantly greater contrast enhancement and significantly less acoustic shadowing. No serious adverse events were reported in either study arm. There were no clinically meaningful adverse laboratory trends, and vital signs, electrocardiographic parameters, oxygen saturation, and respiratory rate remained stable throughout dosing and observation.
Preclinical formulation studies demonstrated substantially less lipid degradation for MVT-100 than Definity under accelerated storage conditions. MVT believes the improved formulation stability may contribute to CardiSon’s prolonged storage profile. Currently marketed Definity requires refrigerated storage before activation, whereas CardiSon will be stored at room temperature. In animal studies, MVT-100 also demonstrated substantially lower renal retention than Definity.
“CardiSon was designed to improve both the clinical imaging performance and practical product characteristics of currently available ultrasound enhancing agents,” said Dr. Unger. “The Phase II results are particularly encouraging because the improvements in left ventricular opacification and reduction in acoustic shadowing were observed by independent blinded readers. The formulation stability and lower renal retention seen in our preclinical studies provide additional evidence of meaningful product differentiation and support continued pivotal development of CardiSon.”
MVT-100 is being developed as an ultrasound enhancing agent for echocardiography. The company’s broader technology platform also includes microbubble and nanobubble-based products for diagnostic and therapeutic ultrasound applications, including CardiSon™, Solv™ and NanoBlate™.
The 40th International Bubble Conference brings together global leaders in cardiology, radiology, vascular medicine, pediatrics and ultrasound research to discuss advances in contrast-enhanced ultrasound and emerging diagnostic and therapeutic applications.
About Microvascular Therapeutics
Microvascular Therapeutics, Inc. is a clinical-stage biotechnology and medical-device company developing next-generation microbubble and nanobubble technologies for diagnostic and therapeutic ultrasound. The company’s lead program, CardiSon™ (MVT-100), is being developed as a next-generation ultrasound enhancing agent for echocardiography. MVT is also developing therapeutic ultrasound platforms for cardiovascular disease and oncology.
For more information, visit www.mvtpharma.com.
Media/Investor Contact
Evan Unger, M.D., FACR
CEO & Executive Chairman
Microvascular Therapeutics, Inc.
e.unger@mvtpharma.com
(520) 730-3264
Forward-Looking Statements
This press release contains forward-looking statements regarding the development, regulatory progress and potential clinical and commercial applications of MVT-100 and other MVT product candidates. These statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied. MVT-100 is an investigational product and has not been approved by the U.S. Food and Drug Administration.
Trademark Notice
DEFINITY® is a registered trademark of Lantheus Medical Imaging, Inc. Microvascular Therapeutics, Inc. is not affiliated with or endorsed by Lantheus Medical Imaging, Inc.
Contact
Microvascular Therapeutics
Emmanuelle Meuillet
520-730-3264
mvtpharma.com
Emmanuelle Meuillet
520-730-3264
mvtpharma.com
Contact
Categories